Mitotane treatment for adrenocortical carcinoma: an overview.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Minerva Endocrinologica

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 22382612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.

  2011cited by this paper
• Clinical management of adrenocortical carcinoma.

  2009cited by this paper
• Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma

  2009cited by this paper
• Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.

  2008cited by this paper
• Adrenocortical carcinoma in the United States

  2008cited by this paper
• Adjuvant mitotane therapy of adrenal cancer - use and controversy.

  2007cited by this paper
• Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

  2007cited by this paper
• Adjuvant mitotane treatment for adrenocortical carcinoma.

  2007cited by this paper
• Adjuvant mitotane in adrenocortical carcinoma.

  2007cited by this paper
• Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results

  2006cited by this paper
• Adrenocortical carcinoma -- improving patient care by establishing new structures.

  2006cited by this paper
• Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.

  2006cited by this paper
• Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

  2006cited by this paper
• Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil

  2006cited by this paper
• Management of patients with adrenal cancer: recommendations of an international consensus conference.

  2005cited by this paper
• Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.

  2005cited by this paper
• Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.

  2004cited by this paper
• Management of adrenocortical carcinoma

  2004cited by this paper
• The clinically inapparent adrenal mass: update in diagnosis and management.

  2004cited by this paper
• Management of the Clinically Inapparent Adrenal Mass (Incidentaloma)

  2003cited by this paper
• A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma

  2002cited by this paper
• Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.

  2002cited by this paper
• Adrenal cortical carcinoma presenting initially with radius metastasis.

  2002cited by this paper
• Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group

  2001cited by this paper
• Impact of monitoring plasma 1,1‐dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma

  2001cited by this paper
• An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma

  2001cited by this paper
• Adrenocortical carcinoma: surgical progress or status quo?

  2001cited by this paper
• Adrenal cortical carcinoma

  2001cited by this paper
• Clinical results of the use of mitotane for adrenocortical carcinoma.

  2000cited by this paper
• Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.

  2000cited by this paper
• Conventional and novel strategies in the treatment of adrenocortical cancer.

  2000cited by this paper
• Adrenocortical carcinoma: clinical and laboratory observations.

  2000cited by this paper
• Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma

  2000cited by this paper
• Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.

  2000cited by this paper
• Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.

  1999cited by this paper
• Adrenocortical carcinoma

  1999cited by this paper
• Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.

  1999cited by this paper
• Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma

  1998cited by this paper
• Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM.

  1998cited by this paper
• Adrenocortical carcinoma: experience in 45 patients.

  1997cited by this paper
• Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma.

  1997cited by this paper
• Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici.

  1997cited by this paper
• Risk factors for adrenal cancer: An exploratory study

  1996cited by this paper
• Adrenocortical carcinoma. A clinical study and treatment results of 52 patients

  1995cited by this paper
• Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

  1994cited by this paper
• Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer.

  1993cited by this paper
• Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.

  1993cited by this paper
• Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature

  1993cited by this paper
• Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer

  1993cited by this paper
• Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery.

  1992cited by this paper
• Survival rates and prognostic factors in adrenocortical carcinoma

  1992cited by this paper
• An eleven-year experience with adrenocortical carcinoma.

  1992cited by this paper
• P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma.

  1992cited by this paper
• Adrenal cortical carcinoma in Norway, 1970–1984

  1992cited by this paper
• Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma.

  1991cited by this paper
• Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas.

  1991cited by this paper
• Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

  1990cited by this paper
• Adrenal cortical carcinoma

  1989cited by this paper
• The Cleveland Clinic experience with adrenal cortical carcinoma.

  1989cited by this paper
• HEPATIC MICROSOMAL ENZYME INDUCTION AND ADRENAL CRISIS DUE TO o,p’DDD THERAPY FOR METASTATIC ADRENOCORTICAL CARCINOMA

  1989cited by this paper
• The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.

  1984cited by this paper
• Complete response of metastasized adrenal cortical carcinoma with o,p'‐ddd.Case report and literature review

  1984cited by this paper
• Treatment of adrenal carcinomas.

  1982cited by this paper
• CIS‐PLATINUM TREATMENT OF METASTATIC ADRENAL CARCINOMA

  1980cited by this paper
• Cytotoxic chemotherapy in adrenal cortical carcinoma.

  1980cited by this paper
• o,p′‐DDD (mitotane) therapy of adrenal cortical carcinoma. Observations on drug dosage, toxicity, and steroid replacement

  1978cited by this paper
• Mitotane use in inoperable adrenal cortical carcinoma.

  1973cited by this paper
• Treatment of adrenocortical carcinoma with o,p'-DDD.

  1972cited by this paper
• Ultrastructure of adrenal cortex of the dog during treatment with DDD.

  1962cited by this paper
• Effects of o,p' DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex.

  1959cited by this paper
• The chemical fractionation of an adrenocorticolytic drug.

  1958cited by this paper
• Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE).

  1949cited by this paper

• GIANT NON-FUNCTIONING ADRENOCORTICAL CARCINOMA

  2023cites this paper
• A Case of Adrenocortical Carcinoma With a Favorable Tumor Control by Radiofrequency Ablation for Liver Metastasis

  2023cites this paper
• Adrenocortical carcinoma (ACC) with massive liver metastases in a 4-year-old female patient: the significance of chemotherapy and imaging studies in treatment and diagnosis – a case report

  2023cites this paper
• A case report and literature review

  2019cites this paper
• Adrenal Tumours: Adrenocortical Functioning Adenomas, Pheochromocytomas, Incidentalomas, and Adrenocortical Cancer

  2019cites this paper
• Identification of DLK1-positive cell clusters in the human adrenal cortex and their potential involvement in adrenocortical carcinoma

  2019cites this paper
• Prolonged Adrenal Insufficiency After Discontinuation Of Mitotane Therapy.

  2019cites this paper
• Successful treatment of metastatic adrenocortical carcinoma in the spine

  2019cites this paper
• Adrenocortical carcinoma in a young adult male with chronic urticaria: A case report and literature review

  2019cites this paper
• High perioperative morbidity and mortality in patients with malignant nonfunctional adrenal tumors.

  2017cites this paper
• Case Report: Adrenocortical Carcinoma with a Solitary Fibrous Tumor

  2017cites this paper
• Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography

  2016cites this paper
• Adrenocortical Carcinoma Treated by CyberKnife.

  2016cites this paper
• Tumores de la glándula suprarrenal

  2016cites this paper
• Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas.

  2016cites this paper
• Tumeurs de la surrénale

  2016cites this paper
• Metastatic adrenal cortical carcinoma to T12 vertebrae.

  2016cites this paper
• microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges

  2016cites this paper
• The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition.

  2016cites this paper
• Stimulation of Erythrocyte Cell Membrane Scrambling by Nystatin

  2015cites this paper
• Diagnostisches und therapeutisches Vorgehen beim Nebennierenrindenkarzinom

  2015cites this paper
• Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment

  2015cites this paper
• [Adrenocortical carcinoma: Update in 2014].

  2014cites this paper
• Corticosurrénalome : nouveautés en 2014 : Pathologie des surrénales.

  2014cites this paper
• Metastatic adrenocortical carcinoma with a prolonged response to mitotane.

  2014cites this paper
• Characteristization of microencapsulated human adrenal cortex tissue in long-term culture

  2014cites this paper
• Stimulation of Erythrocyte Cell Membrane Scrambling by Mitotane

  2014cites this paper
• Case report: Beneficial effect of 11β‐hydroxylase inhibitor in the management of an elderly patient with an androgen‐producing inoperable adrenal tumor

  2013cites this paper
• Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.

  2013cites this paper
• Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.

  2013cites this paper
• Does magnesium level play a role in the association between major depression and cortisol?

  2013cites this paper
• Update in adrenocortical carcinoma.

  2013cites this paper